All lobbying filings
AVENUE SOLUTIONS
Lobbying for JAZZ PHARMACEUTICALS, INC. · Specialty pharmaceuticals
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
California
Lobbying activity
2
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; H.R. 946/S. 1862, ORPHAN Cures Act; S. 3019, No Big Blockbuster Bailouts Act (NOBBBA)